Zinc Finger Repressors mediate widespread PRNP lowering in the nonhuman primate brain and profoundly extend survival in prion disease mice
Authors:
Preprint
Abstract
Prion disease is a rapidly progressing and invariably fatal neurodegenerative disorder with no approved treatment. The disease is caused by the self-templated misfolding of the prion protein (PrP) into toxic species, ultimately leading to neurodegeneration and death. We evaluated a novel epigenetic regulation approach using Zinc Finger Repressors (ZFRs) to ablate PrP expression at the transcriptional level. When delivered using adeno-associated virus (AAV), ZFRs potently and specifically reduced prion mRNA expression by >95% in vitro and to near undetectable levels within single neurons in vivo . In wildtype mice, ZFRs stably lowered neuronal PrP expression throughout the central nervous system for at least 17 months. In mice inoculated with misfolded PrP, AAV-ZFRs given at either early or late disease stages profoundly extended lifespan, significantly reduced PrP in the brain, and improved an array of molecular, histological, biomarker, and behavioral readouts. Finally, we delivered a ZFR targeting the human prion gene ( PRNP) to cynomolgus monkeys using a novel blood-brain-barrier penetrant AAV capsid. Extensive bulk and single-cell assessments revealed widespread ZFR expression and PRNP repression in all 35 brain regions assessed, providing the first demonstration of epigenetic regulation across the nonhuman primate neuraxis following a single intravenous (IV) dose. These results highlight the potential of a one-time IV administered ZFR treatment for prion disease and other neurological disorders.Keywords
This publication has 66 references indexed in Scilit:
- Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob diseaseThe Lancet Neurology, 2021
- Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?Molecular Therapy - Methods & Clinical Development, 2020
- Towards a treatment for genetic prion disease: trials and biomarkersThe Lancet Neurology, 2020
- Therapeutic AAV Gene Transfer to the Nervous System: A Clinical RealityNeuron, 2019
- Generation of goats lacking prion proteinMolecular Reproduction and Development, 2008
- GFAP promoter elements required for region‐specific and astrocyte‐specific expressionGlia, 2008
- Prion Protein BiologyCell, 1998
- High Prion and PrPSc Levels but Delayed Onset of Disease in Scrapie-Inoculated Mice Heterozygous for a Disrupted PrP GeneMolecular Medicine, 1994
- No propagation of prions in mice devoid of PrPCell, 1994
- Mice devoid of PrP are resistant to scrapieCell, 1993